Atai Life Sciences Stock (NASDAQ:ATAI)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$1.06

52W Range

$1.02 - $2.85

50D Avg

$1.28

200D Avg

$1.63

Market Cap

$194.65M

Avg Vol (3M)

$605.46K

Beta

0.78

Div Yield

-

ATAI Company Profile


Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

DE

Employees

83

IPO Date

Jun 18, 2021

Website

ATAI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Research And Development Services$300.00K$200.00K$600.00K

Fiscal year ends in Dec 23 | Currency in USD

ATAI Financial Summary


Dec 23Dec 22Dec 21
Revenue-$233.00K$20.38M
Operating Income$-125.47M$-144.79M$-135.81M
Net Income$-40.22M$-141.41M$-132.61M
EBITDA$-125.47M$-144.07M$-104.84M
Basic EPS$-0.25$-0.91$-0.96
Diluted EPS$-0.25$-0.91$-0.96

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 22Nov 11, 22 | 10:02 AM
Q2 22Aug 15, 22 | 1:20 PM
Q1 22May 16, 22 | 2:02 PM

Peer Comparison


TickerCompany
EWTXEdgewise Therapeutics, Inc.
GHRSGH Research PLC
BPTHBio-Path Holdings, Inc.
MNMDMind Medicine (MindMed) Inc.
FBIOFortress Biotech, Inc.
SEELSeelos Therapeutics, Inc.
VCNXVaccinex, Inc.
ITOSiTeos Therapeutics, Inc.
MOLNMolecular Partners AG
OPTOpthea Limited
ELYMEliem Therapeutics, Inc.